MedTrace Logo

CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women

NCT00058032 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 202638

Last updated 2020-11-19

No results posted yet for this study

Summary

RATIONALE: Screening tests may help doctors detect ovarian cancer early when the survival is much more encouraging. It is not yet known whether a CA125-based or ultrasound strategy is more effective in detecting ovarian cancer early thereby impacting on the mortality from the disease in postmenopausal women from the general population.

PURPOSE: Randomized clinical trial to assess the impact of screening using a multimodal strategy using CA125 interpreted by the Risk of Ovarian Cancer Algorithm (ROCA) followed by transvaginal ultrasound as a second line test versus transvaginal ultrasound on mortality from the disease in postmenopausal women from the general population.

Conditions

Interventions

OTHER

screening questionnaire administration

PROCEDURE

annual screening

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • The Eve Appeal

    collaborator UNKNOWN

  • Medical Research Council

    collaborator OTHER_GOV

  • Cancer Research UK

    collaborator OTHER

  • University College, London

    lead OTHER

Principal Investigators

  • Usha Menon, MBBS, MRCOG · University College, London

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
74 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-04-17
Primary Completion
2005-09-29
Completion
2020-06-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00058032 on ClinicalTrials.gov